The National Institute for Health and Care Excellence (NICE) has recommended Bayer Healthcare’s Xarelto (rivaroxaban) as an effective treatment to reduce the risk of secondary events in acute coronary syndrome (ACS).
Rivaroxaban reduces the risk of ACS secondary events, such as a heart attack, stroke and death.
Go deeper with GlobalData
The Final Appraisal Determination (FAD) is the final phase in a multi-step review process by NICE, which recognised the improved patient outcomes using Xarelto as a treatment option on top of dual antiplatelet therapy.
NICE Health Technology Evaluation Centre Director professor Carole Longson said: "Based on the evidence considered, the independent appraisal committee concluded that rivaroxaban, in combination with aspirin plus clopidogrel, or aspirin alone, was more effective than aspirin plus clopidogrel, or aspirin alone, for preventing further cardiovascular deaths and heart attacks in people with acute coronary syndrome and raised cardiac biomarkers."
The FAD was based on a review of the clinical effectiveness of 2.5mg Xarelto twice-daily in the randomised controlled study, in which Xarelto demonstrated significant advantages in the secondary prevention of ACS in patients with elevated cardiac biomarkers without prior stroke or transient ischaemic attack (TIA).
NICE noted that the dual pathway treatment strategy tested in Atlas ACS 2 TIMI 51 recognised the importance of thrombin generation following ACS events, and confirmed the clinical benefits that the anticoagulant Xarelto 2.5mg twice daily can deliver on top of dual antiplatelet therapy.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataBayer HealthCare UK medical director Dr Luis Felipe Graterol said: "We’re delighted with this FAD as it expands the clinical utility of Xarelto across different settings and patient populations, providing even more patients with access and improved outcomes.
"Xarelto is approved to prevent and treat more thromboembolic conditions than any other novel oral anticoagulant and is the leader in the market place, both in the UK and worldwide."
Image: Bayer HealthCare office building in Wedding district of Berlin, Germany. Photo: courtesy of ChristianSchd.
